Oscar Health (OSCR) Surge on 2026 Revenue Outlook Despite Q4 Miss

Oscar Health (NYSE:OSCR) rose 4.8% on February 09, 2026, following an upbeat 2026 outlook that outpaced a wider-than-expected Q4 loss. The insurer posted a fourth-quarter loss of $1.24 per share and revenue of $2.81 billion, both below estimates. However, it forecast full-year 2026 revenue of $18.85 billion at the midpoint, well ahead of the $12.76 billion consensus. The shares later retreated to $13.18, a 4.1% gain from the prior close. Key context: The stock is highly volatile with 55+5% moves in the past year. Institutional sales weighed on sentiment; Blue Square Asset Management sold 17,462 shares in its 13F filing, and multiple large investors have adjusted positions. OSCR is down 12% YTD and 41.3% from its 52-week high of $22.47 as of February 09, 2026. A $1,000 IPO investment is worth $378.74 today.